Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
SAN DIEGO, Sept. 6, 2013 /PRNewswire/ — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch Global Healthcare Conference in London. The presentation is scheduled for Thursday, September 12(th) at 9:30 a.m. London Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company’s Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company’s other product candidate, Empatic(TM), has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
Media Contact: Orexigen Contact: McDavid Stilwell Denise Powell VP, Corporate Communications and Business Development BrewLife (858) 875-8629 (510) 703-9491
SOURCE Orexigen Therapeutics, Inc.